"Cytosine Deaminase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme which catalyzes the deamination of CYTOSINE resulting in the formation of URACIL. It can also act on 5-methylcytosine to form THYMIDINE.
| Descriptor ID |
D043525
|
| MeSH Number(s) |
D08.811.277.151.486.625
|
| Concept/Terms |
Cytosine Deaminase- Cytosine Deaminase
- Deaminase, Cytosine
- Cytosine Aminohydrolase
- Aminohydrolase, Cytosine
|
Below are MeSH descriptors whose meaning is more general than "Cytosine Deaminase".
Below are MeSH descriptors whose meaning is more specific than "Cytosine Deaminase".
This graph shows the total number of publications written about "Cytosine Deaminase" by people in this website by year, and whether "Cytosine Deaminase" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 2 | 1 | 3 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 2 | 3 |
| 2008 | 5 | 0 | 5 |
| 2009 | 2 | 0 | 2 |
| 2010 | 3 | 1 | 4 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 2 | 3 |
| 2013 | 5 | 3 | 8 |
| 2014 | 2 | 3 | 5 |
| 2015 | 4 | 0 | 4 |
| 2016 | 0 | 2 | 2 |
| 2017 | 0 | 4 | 4 |
| 2018 | 4 | 2 | 6 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 1 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 3 | 3 |
Below are the most recent publications written about "Cytosine Deaminase" by people in Profiles.
-
Therapeutic activity of retroviral replicating vector-mediated gene therapy in combination with anti-PD-1 antibody in a murine pancreatic cancer model. Cancer Gene Ther. 2024 Sep; 31(9):1390-1401.
-
Protein Interaction Map of APOBEC3 Enzyme Family Reveals Deamination-Independent Role in Cellular Function. Mol Cell Proteomics. 2024 May; 23(5):100755.
-
Targeted Suicide Gene Therapy with Retroviral Replicating Vectors for Experimental Canine Cancers. Int J Mol Sci. 2024 Feb 24; 25(5).
-
Therapeutic Efficacy of Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors for Human Ovarian Cancer. Anticancer Res. 2023 Dec; 43(12):5311-5317.
-
CRISPR/Cas9-mediated base-editing enables a chain reaction through sequential repair of sgRNA scaffold mutations. Sci Rep. 2021 Dec 13; 11(1):23889.
-
Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer. Expert Opin Biol Ther. 2021 09; 21(9):1199-1214.
-
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial. JAMA Oncol. 2020 12 01; 6(12):1939-1946.
-
Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model. Int J Mol Sci. 2020 Feb 20; 21(4).
-
Combinatorial targeting of cancer bone metastasis using mRNA engineered stem cells. EBioMedicine. 2019 Jul; 45:39-57.
-
Flucytosine resistance in Cryptococcus gattii is indirectly mediated by the FCY2-FCY1-FUR1 pathway. Med Mycol. 2018 Oct 01; 56(7):857-867.